# Trial of Atezolizumab, Bevacizumab, and Tiragolumab in Patients With Microsatellite Stable, Metastatic Colorectal Cancer

> **NCT06784947** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **University of Colorado, Denver** · enrollment: 13 (actual)

## Conditions studied

- Microsatellite Stable (MSS) Colorectal Cancer (CRC)
- Metastatic Colorectal Cancer (CRC)
- Colorectal Cancer Stage IV

## Interventions

- **PROCEDURE:** Pre-Treatment Biopsy
- **PROCEDURE:** On-Treatment Biopsy
- **DRUG:** Tiragolumab
- **DRUG:** Atezolizumab
- **DRUG:** Bevacizumab

## Key facts

- **NCT ID:** NCT06784947
- **Lead sponsor:** University of Colorado, Denver
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2025-03-25
- **Primary completion:** 2025-09-18
- **Final completion:** 2028-05
- **Target enrollment:** 13 (ACTUAL)
- **Last updated:** 2025-10-02

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06784947

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06784947, "Trial of Atezolizumab, Bevacizumab, and Tiragolumab in Patients With Microsatellite Stable, Metastatic Colorectal Cancer". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT06784947. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*